Liposomal irinotecan for advanced neuroendocrine carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) in people whose advanced neuroendocrine carcinoma has stopped responding to standard first-line treatment. The goal is to see if this special formulation can help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of cancer called poorly differentiated neuroendocrine carcinoma (a fast-growing tumor) that is grade 3, and it has spread or cannot be removed with surgery.
- You have already tried at least one standard chemotherapy and it either stopped working or came back within 6 months after finishing treatment.
- You have not had treatment with the drug irinotecan before.
- You are generally able to care for yourself (a performance score of 0 or 1).
- Your doctor expects you to live at least 3 more months.
- Your blood counts and liver/kidney function are within acceptable ranges.
- You are willing to use effective birth control during the study and for 3 months after the last dose.
- Your brain metastases (if any) are under control and not causing symptoms or need for steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a new combination treatment with irinotecan liposome for advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line therapy. It aims to see if this treatment can help control the cancer and improve outcomes.
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.